Title

Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results.

Authors

Alexis Ogdie
Mei Liu
Meghan Glynn
Kelechi Emeanuru
Leslie Harrold
Sven Richter
Benoit Guerette
Philip Mease, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, USAFollow

Document Type

Article

Publication Date

11-15-2020

Publication Title

The Journal of rheumatology

Abstract

OBJECTIVE: Therapeutic response was evaluated among new apremilast, methotrexate, or biologic disease-modifying anti-rheumatic drug (bDMARD) initiators with oligoarticular psoriatic arthritis (PsA).

METHODS: Patients with oligoarticular PsA in the Corrona PsA/Spondyloarthritis Registry initiating treatment with apremilast, methotrexate, or bDMARD and completing 6-month follow-up were included.

RESULTS: In total, 150 patients initiated monotherapy (apremilast: n=34; methotrexate: n=15; bDMARD: n=101). Apremilast initiators had higher baseline disease activity than methotrexate initiators. At follow-up, apremilast initiators experienced numerically greater disease activity improvements than methotrexate initiators and similar improvements to bDMARD initiators.

CONCLUSION: Findings suggest apremilast monotherapy is an effective option for patients with oligoarticular PsA.

Clinical Institute

Orthopedics & Sports Medicine

Department

Orthopedics

Department

Rheumatology

Recommended Citation

Ogdie, Alexis; Liu, Mei; Glynn, Meghan; Emeanuru, Kelechi; Harrold, Leslie; Richter, Sven; Guerette, Benoit; and Mease, Philip, "Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results." (2020). Articles, Abstracts, and Reports. 4065.
https://digitalcommons.providence.org/publications/4065